Jazz Pharmaceuticals plc
JAZZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4,069 | $3,834 | $3,659 | $3,094 |
| % Growth | 6.1% | 4.8% | 18.3% | – |
| Cost of Goods Sold | $446 | $436 | $541 | $441 |
| Gross Profit | $3,623 | $3,399 | $3,119 | $2,653 |
| % Margin | 89% | 88.6% | 85.2% | 85.8% |
| R&D Expenses | $884 | $850 | $590 | $506 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,385 | $1,343 | $1,417 | $1,452 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $637 | $627 | $1,177 | $526 |
| Operating Expenses | $2,907 | $2,820 | $3,184 | $2,483 |
| Operating Income | $717 | $579 | -$66 | $170 |
| % Margin | 17.6% | 15.1% | -1.8% | 5.5% |
| Other Income/Exp. Net | -$248 | -$284 | -$317 | -$284 |
| Pre-Tax Income | $469 | $295 | -$383 | -$114 |
| Tax Expense | -$91 | -$120 | -$159 | $216 |
| Net Income | $560 | $415 | -$224 | -$329 |
| % Margin | 13.8% | 10.8% | -6.1% | -10.6% |
| EPS | 9.06 | 6.55 | -3.58 | -5.51 |
| % Growth | 38.3% | 283% | 35% | – |
| EPS Diluted | 8.65 | 6.1 | -3.58 | -5.51 |
| Weighted Avg Shares Out | 62 | 63 | 63 | 60 |
| Weighted Avg Shares Out Dil | 66 | 72 | 63 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $238 | $289 | $288 | $279 |
| Depreciation & Amortization | $660 | $639 | $629 | $552 |
| EBITDA | $1,522 | $1,449 | $1,469 | $1,028 |
| % Margin | 37.4% | 37.8% | 40.1% | 33.2% |